**Joint Regulators-Industry Working Group: Integrated Strategies for Safety Assessments of Cosmetic Ingredients**

The purpose of *ad hoc* Joint Regulators-Industry Working Group (WG) is to outline principles that underpin the integration of novel methods and data in an exposure-led approach for the safety assessment of cosmetic ingredients.

Novel methods that need to be considered include in-vitro tests, (quantitative) structure activity relationships [(Q)SARs], computational methods (including exposure models), and other evolving safety assessment tools.

It is understood that the science in these areas is rapidly evolving, with a large number of models and approaches referenced in the literature, ranging from exploratory to those that can be considered mature and well developed but whose applicability domain is outside of cosmetics. There is therefore a need for safety assessors to understand how these tools may be used alongside existing data to ensure robust safety decision making.

The WG should consider the strengths and limitations of some of the different approaches that could be used in 21st Century decision making, what they tell us, and how they may be used. This could include the range of available approaches from credible sources including ICATM, OECD, and the mature components of such programs as SEURAT-1 in the EU, TOX21 in the USA, and others.  Previous work by ICCR will also be taken into account and where appropriate built on.

The first deliverable from this effort will be an overview of how these assessment tools may be integrated to assess the safety of ingredients used in cosmetics.

The WG will inform the ICCR Steering Committee regularly on its progress. Deliverables include:

* Presentation of revised ToRs for endorsement by ICCR-10 in 2016.
* Report describing the principles underpinning an exposure-led approach to the integration of novel approaches in safety decision making in 2017

The group of experts should include both regulators and industry participants, and the aggregated expertise of the WG includes:

* Knowledge of toxicology tools (including QSAR, computational methods, in vitro tests; method/model validation; adverse outcome pathways; use of clinical data; integrated testing strategies, or related disciplines);
* Experience in the application of alternative methods and strategies (e.g. IATA) to support integrated safety assessment (such as *in vivo, in vitro* and *in silico* data) of cosmetics;
* The use of these emerging technologies to meet the needs of a cosmetics safety evaluation;

Nominated experts should have company/association/ government support to review documents, participate in regular calls among the WG and, if deemed necessary, attend one in-person meeting during the ICCR-10, cycle in 2016.

Given the highly specialized nature of this work proposal, *ad hoc* experts may be identified and invited to participate, as required in specific elements of the work. The identification and participation of such *ad hoc* experts on a case by case basis should be at the discretion of the WG participants and co-chairs.

**Joint Regulators-Industry Working Group Participants**

|  |  |  |
| --- | --- | --- |
| **Organization** | **Name** | **E-mail** |
| ANVISA | Julcemara Gresselle de Oliveira | Julcemara.oliveira@anvisa.gov.br |
| ANVISA | Ana Carolina | ANA.FALEIROS@anvisa.gov.br |
| ABIHPEC | Marcio Lorencini | marciolo@grupoboticario.com.br |
| ABIHPEC | Ariadne Morais | ariadne@abihpec.org.br |
| Health Canada | Eric Vaillancourt | [eric.vaillancourt@hc-sc.gc.ca](mailto:eric.vaillancourt@hc-sc.gc.ca) |
| Cosmetics Alliance Canada | Petra Kern (P&G) | [kern.ps@pg.com](mailto:kern.ps@pg.com) |
| Cosmetics Alliance Canada | Beta Montemayor | bmontemayor@cosmeticsalliance.ca |
| European Commission | Joao Barroso | Joao.barroso@ec.europa.eu |
| Cosmetics Europe | **Matt Dent (Unilever) \*Co-Chair** | [Matthew.Dent@unilever.com](mailto:Matthew.Dent@unilever.com) |
| Cosmetics Europe | Rob Taalman | [rtaalman@cosmeticseurope.eu](mailto:rtaalman@cosmeticseurope.eu) |
| Cosmetics Europe | Elsa Dietrich | edietrich@cosmeticseurope.eu |
| Cosmetics Europe | Gladys Ouedraogo | gouedraogo@rd.loreal.com |
| EffCI | Reinhard Kreiling (Clariant Produkte GmbH) | [reinhard.kreiling@clariant.com](mailto:reinhard.kreiling@clariant.com) |
| MHLW/PMDA | Akihiko Hirose | [hirose@nihs.go.jp](mailto:hirose@nihs.go.jp) |
| MHLW/PMDA | **Hajime Kojima \*Co-Chair** | [h-kojima@nihs.go.jp](mailto:h-kojima@nihs.go.jp) |
| JCIA | Masato Hatao (JCIA) | hatao@jcia.org |
| JCIA | Yutaka Kasai (Kao) | [kasai.yutaka@kao.co.jp](mailto:kasai.yutaka@kao.co.jp) |
| JCIA | Tetsuya Kambe | kambe@jcia.org |
| US FDA | Rajeshwar Verma | Rajeshwar.Verma@fda.hhs.gov |
| ICMAD | Craig Weiss (Cosmetic Product Testing Co.) | [crweiss@cptclabs.com](mailto:crweiss@cptclabs.com) |
| PCPC | Jay Ansell | [ansellj@personalcarecouncil.org](mailto:ansellj@personalcarecouncil.org) |
| Taiwan FDA | Chia-Jung, Chang | ccj0920@fda.gov.tw |
| Taiwan FDA | Han-Sheng Chien | protein06@fda.gov.tw |
| Taiwan FDA | Yin Chu | ashley@fda.gov.tw |
| TWCIA (Taiwan) | Chien Yang | k77982@kao.com.tw |
| TWCIA (Taiwan) | Ya-Chi, Chan | ychan@kao.com.tw |